A health startup has raised 拢2 million for at-home testing using biomarkers.
London-based Sanome raised its first round of funding from a number of leading UK and European HealthTech specialist investors.
The round was led by Heal Capital, with participation from Crista Galli Ventures, Selvedge Ventures, o2h Ventures, Meltwind and a number of high-profile angels including David Cleevely and Pam Garside.
Sanome has developed a diagnostics innovation engine that combines biomarkers to develop medical grade, at-home diagnostic products more efficiently and effectively. Most digital health, wearables and consumer biotech tools have limited medical use because it鈥檚 hard to validate them clinically.聽
Sanome鈥檚 novel approach leverages these existing technologies to develop at-home tests that are clinically validated to improve patient outcomes and reduce healthcare costs – ultimately laying the foundation for the early detection and prevention of diseases of high unmet need.
Sanome was founded by experienced entrepreneurs Benedikt von Th眉ngen (CEO) and Dr Marc van der Schee (Chief Medical Officer). They combine a unique set of experiences including software, clinical, healthcare, AI/ ML and biomarker development, as well as having built and scaled multiple successful companies before, including Owlstone Medical and Speechmatics.
/blog/2021/09/07/biotech-behind-covid-drug-raises-pre-ipo-3-5m-round/
The investment will be used to expand the team across London, Amsterdam, and Cambridge; deliver on key strategic and commercial partnerships to develop and validate the first set of IVD candidates.
鈥淗ealthcare touches each and every one of us and the recent pandemic has highlighted that at a global level,鈥� said CEO Von Th眉ngen.聽
鈥淚t showed the need to bring healthcare closer to people鈥檚 homes and that we need to leverage many of the recent innovations in digital health and consumer BioTech to capture as many data points about human health as possible.聽
鈥淭his will transform our understanding of the human body and our approach to disease detection and management.鈥澛�
/medtech-50/
Eckhardt Weber, partner at Heal Capital, commented: 鈥淪anome will change the way patients, providers and payers interact with healthcare.聽
鈥淏y pioneering a new model for IVD innovation, they can create medical-grade diagnostics that truly focus on solving our healthcare system鈥檚 most pressing problems.聽
鈥淲e could not be happier to be supporting Sanome鈥檚 exceptional founding team on the journey to make healthcare inclusive, preventative and proactive.鈥�